NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report report published on Wednesday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NASDAQ NURO opened at $4.37 on Wednesday. The firm’s 50-day moving average price is $4.26 and its two-hundred day moving average price is $4.10. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73. The stock has a market capitalization of $8.97 million, a P/E ratio of -0.95 and a beta of 2.15.

Institutional Investors Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC purchased a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is currently owned by institutional investors and hedge funds.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.